Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance

Anke Nijhuis, Hannah Thompson, Julie Adam, Alexandra Parker, Luke Gammon, Amy Lewis, Jacob G. Bundy, Tomoyoshi Soga, Aisha Jalaly, David Propper, Rosemary Jeffery, Nirosha Suraweera, Sarah McDonald, Mohamed A. Thaha, Roger Feakins, Robert Lowe, Cleo L. Bishop, Andrew Silver

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Solid tumours have oxygen gradients and areas of near and almost total anoxia. Hypoxia reduces sensitivity to 5-fluorouracil (5-FU)-chemotherapy for colorectal cancer (CRC). MicroRNAs (miRNAs) are hypoxia sensors and were altered consistently in six CRC cell lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S) maintained in hypoxia (1 and 0.2% oxygen) compared with normoxia (20.9%). CRC cell lines also showed altered amino acid metabolismin hypoxia and hypoxia-responsive miRNAs were predicted to target genes in four metabolismpathways: beta-alanine valine, leucine, isoleucine aminoacyl-tRNA; and alanine, aspartate, glutamate. MiR-210 was increased in hypoxic areas of CRC tissues and hypoxia-responsive miR-21 and miR-30d, but not miR-210, were significantly increased in 5-FU resistant CRCs. Treatment with miR-21 and miR-30d antagonists sensitized hypoxic CRC cells to 5-FU. Our data highlight the complexity and tumour heterogeneity caused by hypoxia. MiR-210 as a hypoxic biomarker, and the targeting of miR-21 and miR-30d and/or the amino acid metabolismpathways may offer translational opportunities.

Original languageEnglish
Article numberddx059
Pages (from-to)1552-1564
Number of pages13
JournalHuman Molecular Genetics
Volume26
Issue number8
DOIs
Publication statusPublished - 2017 Apr 15

Fingerprint

MicroRNAs
Fluorouracil
Colorectal Neoplasms
Oxygen
beta-Alanine
Amino Acids
Cell Line
Hypoxia
Isoleucine
Valine
Rectal Neoplasms
Transfer RNA
Aspartic Acid
Leucine
Alanine
Colonic Neoplasms
Glutamic Acid
Neoplasms
Biomarkers
Drug Therapy

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Nijhuis, A., Thompson, H., Adam, J., Parker, A., Gammon, L., Lewis, A., ... Silver, A. (2017). Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. Human Molecular Genetics, 26(8), 1552-1564. [ddx059]. https://doi.org/10.1093/hmg/ddx059

Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. / Nijhuis, Anke; Thompson, Hannah; Adam, Julie; Parker, Alexandra; Gammon, Luke; Lewis, Amy; Bundy, Jacob G.; Soga, Tomoyoshi; Jalaly, Aisha; Propper, David; Jeffery, Rosemary; Suraweera, Nirosha; McDonald, Sarah; Thaha, Mohamed A.; Feakins, Roger; Lowe, Robert; Bishop, Cleo L.; Silver, Andrew.

In: Human Molecular Genetics, Vol. 26, No. 8, ddx059, 15.04.2017, p. 1552-1564.

Research output: Contribution to journalArticle

Nijhuis, A, Thompson, H, Adam, J, Parker, A, Gammon, L, Lewis, A, Bundy, JG, Soga, T, Jalaly, A, Propper, D, Jeffery, R, Suraweera, N, McDonald, S, Thaha, MA, Feakins, R, Lowe, R, Bishop, CL & Silver, A 2017, 'Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance', Human Molecular Genetics, vol. 26, no. 8, ddx059, pp. 1552-1564. https://doi.org/10.1093/hmg/ddx059
Nijhuis, Anke ; Thompson, Hannah ; Adam, Julie ; Parker, Alexandra ; Gammon, Luke ; Lewis, Amy ; Bundy, Jacob G. ; Soga, Tomoyoshi ; Jalaly, Aisha ; Propper, David ; Jeffery, Rosemary ; Suraweera, Nirosha ; McDonald, Sarah ; Thaha, Mohamed A. ; Feakins, Roger ; Lowe, Robert ; Bishop, Cleo L. ; Silver, Andrew. / Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. In: Human Molecular Genetics. 2017 ; Vol. 26, No. 8. pp. 1552-1564.
@article{519c7da99cb244c6843f5fe6f3138763,
title = "Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance",
abstract = "Solid tumours have oxygen gradients and areas of near and almost total anoxia. Hypoxia reduces sensitivity to 5-fluorouracil (5-FU)-chemotherapy for colorectal cancer (CRC). MicroRNAs (miRNAs) are hypoxia sensors and were altered consistently in six CRC cell lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S) maintained in hypoxia (1 and 0.2{\%} oxygen) compared with normoxia (20.9{\%}). CRC cell lines also showed altered amino acid metabolismin hypoxia and hypoxia-responsive miRNAs were predicted to target genes in four metabolismpathways: beta-alanine valine, leucine, isoleucine aminoacyl-tRNA; and alanine, aspartate, glutamate. MiR-210 was increased in hypoxic areas of CRC tissues and hypoxia-responsive miR-21 and miR-30d, but not miR-210, were significantly increased in 5-FU resistant CRCs. Treatment with miR-21 and miR-30d antagonists sensitized hypoxic CRC cells to 5-FU. Our data highlight the complexity and tumour heterogeneity caused by hypoxia. MiR-210 as a hypoxic biomarker, and the targeting of miR-21 and miR-30d and/or the amino acid metabolismpathways may offer translational opportunities.",
author = "Anke Nijhuis and Hannah Thompson and Julie Adam and Alexandra Parker and Luke Gammon and Amy Lewis and Bundy, {Jacob G.} and Tomoyoshi Soga and Aisha Jalaly and David Propper and Rosemary Jeffery and Nirosha Suraweera and Sarah McDonald and Thaha, {Mohamed A.} and Roger Feakins and Robert Lowe and Bishop, {Cleo L.} and Andrew Silver",
year = "2017",
month = "4",
day = "15",
doi = "10.1093/hmg/ddx059",
language = "English",
volume = "26",
pages = "1552--1564",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance

AU - Nijhuis, Anke

AU - Thompson, Hannah

AU - Adam, Julie

AU - Parker, Alexandra

AU - Gammon, Luke

AU - Lewis, Amy

AU - Bundy, Jacob G.

AU - Soga, Tomoyoshi

AU - Jalaly, Aisha

AU - Propper, David

AU - Jeffery, Rosemary

AU - Suraweera, Nirosha

AU - McDonald, Sarah

AU - Thaha, Mohamed A.

AU - Feakins, Roger

AU - Lowe, Robert

AU - Bishop, Cleo L.

AU - Silver, Andrew

PY - 2017/4/15

Y1 - 2017/4/15

N2 - Solid tumours have oxygen gradients and areas of near and almost total anoxia. Hypoxia reduces sensitivity to 5-fluorouracil (5-FU)-chemotherapy for colorectal cancer (CRC). MicroRNAs (miRNAs) are hypoxia sensors and were altered consistently in six CRC cell lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S) maintained in hypoxia (1 and 0.2% oxygen) compared with normoxia (20.9%). CRC cell lines also showed altered amino acid metabolismin hypoxia and hypoxia-responsive miRNAs were predicted to target genes in four metabolismpathways: beta-alanine valine, leucine, isoleucine aminoacyl-tRNA; and alanine, aspartate, glutamate. MiR-210 was increased in hypoxic areas of CRC tissues and hypoxia-responsive miR-21 and miR-30d, but not miR-210, were significantly increased in 5-FU resistant CRCs. Treatment with miR-21 and miR-30d antagonists sensitized hypoxic CRC cells to 5-FU. Our data highlight the complexity and tumour heterogeneity caused by hypoxia. MiR-210 as a hypoxic biomarker, and the targeting of miR-21 and miR-30d and/or the amino acid metabolismpathways may offer translational opportunities.

AB - Solid tumours have oxygen gradients and areas of near and almost total anoxia. Hypoxia reduces sensitivity to 5-fluorouracil (5-FU)-chemotherapy for colorectal cancer (CRC). MicroRNAs (miRNAs) are hypoxia sensors and were altered consistently in six CRC cell lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S) maintained in hypoxia (1 and 0.2% oxygen) compared with normoxia (20.9%). CRC cell lines also showed altered amino acid metabolismin hypoxia and hypoxia-responsive miRNAs were predicted to target genes in four metabolismpathways: beta-alanine valine, leucine, isoleucine aminoacyl-tRNA; and alanine, aspartate, glutamate. MiR-210 was increased in hypoxic areas of CRC tissues and hypoxia-responsive miR-21 and miR-30d, but not miR-210, were significantly increased in 5-FU resistant CRCs. Treatment with miR-21 and miR-30d antagonists sensitized hypoxic CRC cells to 5-FU. Our data highlight the complexity and tumour heterogeneity caused by hypoxia. MiR-210 as a hypoxic biomarker, and the targeting of miR-21 and miR-30d and/or the amino acid metabolismpathways may offer translational opportunities.

UR - http://www.scopus.com/inward/record.url?scp=85019058858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019058858&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddx059

DO - 10.1093/hmg/ddx059

M3 - Article

C2 - 28207045

AN - SCOPUS:85019058858

VL - 26

SP - 1552

EP - 1564

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 8

M1 - ddx059

ER -